FreeBioList

Catalysts / XFOR

X4 Pharmaceuticals (XFOR) catalysts

Upcoming FDA decisions and readouts we track for X4 Pharmaceuticals, each with the filing that announced it.

Listed on — Nasdaq Catalysts tracked — 1 Rows last checked — 11 Sep 2026

FreeBioList tracks 1 upcoming catalyst for X4 Pharmaceuticals (XFOR, listed on Nasdaq). It concerns Mavorixafor (Chronic neutropenia).

First on the list: the Phase 3 readout for Mavorixafor (Chronic neutropenia), guided by the company to H1 2028.

The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 11 Sep 2026. The methodology page explains each status.

Background reading: How to read a Phase 3 topline readout.

Ticker
XFOR
Next catalyst
H1 2028
Type
Phase 3 readout
Listed options
Yes
Company ▾ Drug ▾ Effect / indication Next catalyst ▾ Phase / type ▾ Status ▾ Source Options
X4 Pharmaceuticals XFOR · Nasdaq Mavorixafor Chronic neutropenia H1 2028
company guidance		 Phase 3 readout Verified 8-K exhibit 99.1 ↗ Yes